CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8 enrolled
Drug / intervention
Pegvisomantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01261000
NCT01261000N/ACompleted
CompareCT.gov

Tissue Biomarker for Pegvisomant Action

Cedars-Sinai Medical Center·interventional·Posted Dec 16, 2010·Updated Aug 22, 2017

In Brief

A clinical study evaluating Pegvisomant for Acromegaly. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Acromegaly is a disease of the pituitary gland that involves overproduction of growth hormone. Pegvisomant works by blocking binding of GH to receptors found in tissues throughout the body. Human studies have evaluated pegvisomant action by measuring reduction of IGF-I levels in the blood. However, no studies have evaluated the effects of blocking GH receptors in tissues. In this study, we will study tissue biomarkers for pegvisomant action in GH and IGF-I dependent signaling pathways in colon tissue of patients with acromegaly treated with pegvisomant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 16, 2010
Enrollment StartNov 1, 2010
Primary CompletionMar 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.5 years ago

Interventions

Pegvisomantdrug

Pegvisomant used as indicated